A Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MEDI8897 in Healthy Adults

NCT02114268 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

342

Enrollment

INDUSTRY

Sponsor class

Conditions

Respiratory Syncytial Virus Infections

Interventions

DRUG: MEDI8897 Intravenous
DRUG: Placebo
DRUG: MEDI8897 Intravenous
DRUG: MEDI8897 Intravenous
DRUG: MEDI8897 Intramuscular
DRUG: MEDI8897 Intramuscular

Sponsor

MedImmune LLC